Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms

Molecular and Cellular Biochemistry

Volumn 282, Issue 1-2, 2006, Pages 177-185

  Jiang, Jihong ^a   Yuen, Violet ^a   Xiang, Hong ^a   McNeill, John H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

1bosentan; 2cardiac function; 3endothelin 1(ET 1); 4endothelin receptor blocker; 5protein kinase C (PKC); 6streptozotocin induced diabetes

Indexed keywords

BOSENTAN; ISOPROTEIN; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ZETA; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CLINICAL OBSERVATION; CONTROLLED STUDY; CYTOSOLIC FRACTION; DIABETES MELLITUS; DRUG DOSE REGIMEN; ENZYME ACTIVATION; HEART DISEASE; HEART PERFORMANCE; LONG TERM CARE; MALE; NONHUMAN; PROTEIN CONTENT; PROTEIN LOCALIZATION; RAT; RAT STRAIN; STREPTOZOCIN DIABETES; TISSUE HOMOGENATE; WESTERN BLOTTING;

ANIMALS; BLOOD GLUCOSE; CELL FRACTIONATION; CELL MEMBRANE; CYTOSOL; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATION; GLUCOSE; INSULIN; ISOENZYMES; MALE; MYOCARDIUM; PROTEIN KINASE C; RATS; RATS, WISTAR; RECEPTORS, ENDOTHELIN; SULFONAMIDES; VENTRICULAR FUNCTION, LEFT;

ANIMALIA; RATTUS NORVEGICUS;

EID: 29644440157     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-006-1926-1     Document Type: Article

References (53)

1. Janeczko D, Czyzyk A, Kopczynski J, Krzyzanowski M: Risk factors of cardiovascular death in diabetic patients. Diabet Med 8 Spec No: S100-S103, 1991
2. Galderisi M, Anderson KM, Wilson PW, Levy D: Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 68: 85-89, 1991 2058564
3. Dubrey SW, Reaveley DR, Seed M, Lane DA, Ireland H, O'Donnell M, O'Connor B, Noble MI, Leslie RD: Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes 43: 831-835, 1994 8194671
4. Hopfner RL, Gopalakrishnan V: Endothelin: Emerging role in diabetic vascular complications. Diabetologia 42: 1383-1394, 1999 10651255
5. Candido R, Allen TJ: Haemodynamics in microvascular complications in type 1 diabetes. Diabetes Metab Res Rev 18: 286-304, 2002 12203944
6. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR: Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33: 306-310, 1990 2198188
7. Morabito E, Corsico N, Arrigoni Martelli E: Endothelins urinary excretion is increased in spontaneously diabetic rats: BB/BB. Life Sci 56: PL13-PL18, 1995 7830488
8. King GL, Brownlee M: The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 25: 255-270, 1996 8799700
9. Pribnow D, Muldoon LL, Fajardo M, Theodor L, Chen LY, Magun BE: Endothelin induces transcription of fos/jun family genes: A prominent role for calcium ion. Mol Endocrinol 6: 1003-1012, 1992 1508217
10. Muldoon LL, Pribnow D, Rodland KD, Magun BE: Endothelin-1 stimulates DNA synthesis and anchorage-independent growth of Rat-1 fibroblasts through a protein kinase C-dependent mechanism. Cell Regul 1: 379-390, 1990 2129223
11. Muldoon LL, Rodland KD, Forsythe ML, Magun BE: Stimulation of phosphatidylinositol hydrolysis, diacylglycerol release, and gene expression in response to endothelin, a potent new agonist for fibroblasts and smooth muscle cells. J Biol Chem 264: 8529-8536, 1989 2656683
12. Simonson MS, Jones JM, Dunn MJ: Differential regulation of fos and jun gene expression and AP-1 cis-element activity by endothelin isopeptides. Possible implications for mitogenic signaling by endothelin. J Biol Chem 267: 8643-8649, 1992 1314833
13. Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S: Diabetes-induced myocardial structural changes: Role of endothelin-1 and its receptors. J Mol Cell Cardiol 32: 1621-1629, 2000 10966825
14. Hileeto D, Cukiernik M, Mukherjee S, Evans T, Barbin Y, Downey D, Karmazyn M, Chakrabarti S: Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes Metab Res Rev 18: 386-394, 2002 12397581
15. Chakrabarti S, Chen S, Evans T, Karmazyn M: Endothelins in the microvasculature and heart in diabetes. Adv Exp Med Biol 498: 97-108, 2001 11900407
16. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, Cassal JM, Hirth G, Muller M, Neidhart W, et al.: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270: 228-235, 1994 8035319
17. Verma S, Arikawa E, McNeill JH: Long-term endothelin receptor blockade improves cardiovascular function in diabetes. Am J Hypertens 14: 679-687, 2001 11465653
18. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 89: 11059-11063, 1992 1438315
19. Ishii H, Koya D, King GL: Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 76: 21-31, 1998 9462865
20. Idris I, Gray S, Donnelly R: Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 44: 659-673, 2001 11440359
21. Kang N, Alexander G, Park JK, Maasch C, Buchwalow I, Luft FC, Haller H: Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int 56: 1737-1750, 1999 10571782
22. Liu X, Wang J, Takeda N, Binaglia L, Panagia V, Dhalla NS: Changes in cardiac protein kinase C activities and isozymes in streptozotocin-induced diabetes. Am J Physiol 277: E798-E804, 1999 10567005
23. Guo M, Wu MH, Korompai F, Yuan SY: Upregulation of PKC genes and isozymes in cardiovascular tissues during early stages of experimental diabetes. Physiol Genomics 12: 139-146, 2003 12441406
24. Yuan SY, Ustinova EE, Wu MH, Tinsley JH, Xu W, Korompai FL, Taulman AC: Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes. Circ Res 87: 412-417, 2000 10969040
25. Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, King GL: Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 94: 9320-9325, 1997 9256480
26. Jiang T, Pak E, Zhang HL, Kline RP, Steinberg SF: Endothelin-dependent actions in cultured AT-1 cardiac myocytes. The role of the epsilon isoform of protein kinase C. Circ Res 78: 724-736, 1996 8635230
27. Sugden PH, Clerk A: Cellular mechanisms of cardiac hypertrophy. J Mol Med 76: 725-746, 1998 9826118
28. Wang Y: Signal transduction in cardiac hypertrophy-dissecting compensatory versus pathological pathways utilizing a transgenic approach. Curr Opin Pharmacol 1: 134-140, 2001 11714087
29. Wang P, Gallagher KP, Downey JM, Cohen MV: Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit heart. J Mol Cell Cardiol 28: 579-588, 1996 9011641
30. Wolf SC, Amend T, Risler T, Amann K, Brehm BR: Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond) 103 Suppl 48: 276S-279S, 2002
31. Tickerhoof MM, Farrell PA, Korzick DH: Alterations in rat coronary vasoreactivity and vascular protein kinase C isoforms in type I diabetes. Am J Physiol Heart Circ Physiol, 2003
32. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607-614, 1992 1411571
33. Jiang J, Cyr D, Babbitt RW, Sessa WC, Patterson C: Chaperone-dependent regulation of endothelial nitric-oxide synthase intracellular trafficking by the co-chaperone/ubiquitin ligase CHIP. J Biol Chem 278: 49332-49341, 2003
34. Sokolovsky M: Endothelin receptor subtypes and their role in transmembrane signaling mechanisms. Pharmacol Ther 68: 435-471, 1995 8788566
35. Nishio Y, Kashiwagi A, Kida Y, Kodama M, Abe N, Saeki Y, Shigeta Y: Deficiency of cardiac beta-adrenergic receptor in streptozocin-induced diabetic rats. Diabetes 37: 1181-1187, 1988 2842211
36. i-modulated muscarinic receptor-adenylyl cyclase system in rat myocardium. Pharmacol Toxicol 75: 186-193, 1994 7800662
37. Yang JM, Cho CH, Kong KA, Jang IS, Kim HW, Juhnn YS: Increased expression of Galpha q protein in the heart of streptozotocin-induced diabetic rats. Exp Mol Med 31: 179-184, 1999 10630371
38. Duan J, Zhang HY, Adkins SD, Ren BH, Norby FL, Zhang X, Benoit JN, Epstein PN, Ren J: Impaired cardiac function and IGF-I response in myocytes from calmodulin-diabetic mice: Role of Akt and RhoA. Am J Physiol Endocrinol Metab 284: E366-E376, 2003 12531745
39. Kuwahara K, Saito Y, Nakagawa O, Kishimoto I, Harada M, Ogawa E, Miyamoto Y, Hamanaka I, Kajiyama N, Takahashi N, Izumi T, Kawakami R, Tamura N, Ogawa Y, Nakao K: The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes - Possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett 452: 314-318, 1999 10386613
40. Kobayashi N, Horinaka S, Mita S, Nakano S, Honda T, Yoshida K, Kobayashi T, Matsuoka H: Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 55: 757-767, 2002 12176125
41. Takanashi M, Endoh M: Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium. Am J Physiol 261: H611-H619, 1991 1653535
42. Banyasz T, Magyar J, Kortvely A, Szigeti G, Szigligeti P, Papp Z, Mohacsi A, Kovacs L, Nanasi PP: Different effects of endothelin-1 on calcium and potassium currents in canine ventricular cells. Naunyn Schmiedebergs Arch Pharmacol 363: 383-390, 2001 11330331
43. Ono K, Tsujimoto G, Sakamoto A, Eto K, Masaki T, Ozaki Y, Satake M: Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature 370: 301-304, 1994 8035879
44. 2+ current in guinea-pig ventricular myocytes. J Physiol 503 (Pt 1): 55-65, 1997 9288674
45. 2+ current in dog ventricular myocytes. J Cardiovasc Pharmacol 36: 344-350, 2000 10975592
46. 2+ current in diabetic rat cardiomyocytes. Am J Physiol 274: H1849-H1857, 1998 9841512
47. 2+, phospholipid-dependent protein kinase associated with plasma membrane. Nature 301: 621-623, 1983 6828143
48. Disatnik MH, Buraggi G, Mochly-Rosen D: Localization of protein kinase C isozymes in cardiac myocytes. Exp Cell Res 210: 287-297, 1994 8299726
49. Arikawa E, Verma S, Dumont AS, McNeill JH: Chronic bosentan treatment improves renal artery vascular function in diabetes. J Hypertens 19: 803-812, 2001 11330884
50. Verma S, Arikawa E, Lee S, Dumont AS, Yao L, McNeill JH: Exaggerated coronary reactivity to endothelin-1 in diabetes: Reversal with bosentan. Can J Physiol Pharmacol 80: 980-986, 2002 12450064
51. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G: Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47: 450-456, 1998 9519753
52. Deng D, Evans T, Mukherjee K, Downey D, Chakrabarti S: Diabetes-induced vascular dysfunction in the retina: Role of endothelins. Diabetologia 42: 1228-1234, 1999 10525664
53. Gilbert RE, Rumble JR, Cao Z, Cox AJ, van Eeden P, Allen TJ, Kelly DJ, Cooper ME: Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res 86: 158-165, 2000 10666411